Arrowhead Pharmaceuticals Hits New 52-Week High of $39.42

Arrowhead Pharmaceuticals, Inc. has reached a significant milestone by hitting a new 52-week high of USD 39.42 on October 6, 2025. This achievement underscores the company's notable performance in the pharmaceuticals and biotechnology sector, particularly as it has recorded a remarkable 53.0% increase over the past year, significantly outperforming the S&P 500, which has seen a gain of 17.82% during the same period.
With a market capitalization of USD 3,756 million, Arrowhead Pharmaceuticals is classified as a small-cap company. Despite its recent price surge, the company remains in a loss-making position, reflected in its negative price-to-earnings ratio and return on equity of -30.51%. The stock's price-to-book ratio stands at 7.19, indicating a premium valuation relative to its book value. Additionally, the company has a debt-to-equity ratio of -0.56, suggesting a unique financial structure.

As Arrowhead Pharmaceuticals continues to navigate the competitive landscape of the pharmaceuticals and biotechnology industry, this new high marks an important point in its ongoing journey.